Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Intermittent Selumetinib for Uveal Melanoma

The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the drug Selumetinib will have on subjects with uveal melanoma. Selumetinib is a drug that blocks

alopecia
cancer
karnofsky performance status
neutrophil count
measurable disease
  • 4 views
  • 26 Jan, 2022
  • 3 locations
  • 0 views
  • 27 Jan, 2021
  • 29 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

nervous
tumor markers
selumetinib
chemotherapeutic agents
corticosteroids
  • 1029 views
  • 27 May, 2022
  • 104 locations
Selumetinib and Olaparib in Solid Tumors

selumetinib and olaparib that can be given to patients who have solid tumors that are advanced or recurrent (has returned after treatment). The goal of Phase 2 is to learn if the highest tolerable dose

measurable disease
mammogram
KRAS
  • 11 views
  • 26 Mar, 2022
  • 1 location
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT)

Phase I and II study of the MEK inhibitor Selumetinib given twice daily on 5 out of 7 days in children with NF1 and inoperable plexiform neurofibromas or progressive/relapsed optic pathway

ejection fraction
tumor resection
dysplasia
renal function
gilbert disease
  • 49 views
  • 27 Feb, 2022
  • 1 location
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening

direct bilirubin
anemia
chronic myelomonocytic leukemia
thrombocytosis
myelofibrosis
  • 14 views
  • 25 May, 2022
  • 1 location
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating

  • 0 views
  • 24 May, 2022
  • 31 locations
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex)

This trial is to investigate the combination of selumetinib and dexamethasone in the treatment of acute lymphoblastic leukaemia (ALL) in both adults and children. Phase I is to find the most

dexamethasone
graft versus host disease
  • 80 views
  • 23 Mar, 2022
  • 16 locations
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)

In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor

biological factors
dexamethasone
selumetinib
corticosteroids
cataract
  • 634 views
  • 28 Apr, 2022
  • 1 location
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase 3 trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously

ejection fraction
metastatic disease
residual tumor
carboplatin
selumetinib
  • 14 views
  • 26 May, 2022
  • 56 locations